MA48602A - Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha - Google Patents

Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha

Info

Publication number
MA48602A
MA48602A MA048602A MA48602A MA48602A MA 48602 A MA48602 A MA 48602A MA 048602 A MA048602 A MA 048602A MA 48602 A MA48602 A MA 48602A MA 48602 A MA48602 A MA 48602A
Authority
MA
Morocco
Prior art keywords
modulators
phosphine oxide
compounds substituted
ifn alpha
heteroaryl compounds
Prior art date
Application number
MA048602A
Other languages
English (en)
Inventor
John V Duncia
David S Weinstein
Zili Xiao
Michael G Yang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA48602A publication Critical patent/MA48602A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/650905Six-membered rings having the nitrogen atoms in the positions 1 and 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA048602A 2016-12-13 2017-12-12 Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha MA48602A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662433470P 2016-12-13 2016-12-13

Publications (1)

Publication Number Publication Date
MA48602A true MA48602A (fr) 2020-03-18

Family

ID=60888685

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048602A MA48602A (fr) 2016-12-13 2017-12-12 Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha

Country Status (10)

Country Link
US (1) US10294256B2 (fr)
EP (1) EP3555111B1 (fr)
JP (1) JP7046092B2 (fr)
KR (1) KR102602558B1 (fr)
CN (1) CN110267964B (fr)
AR (1) AR110351A1 (fr)
ES (1) ES2907008T3 (fr)
MA (1) MA48602A (fr)
TW (1) TW201827423A (fr)
WO (1) WO2018111787A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3083122A1 (fr) 2017-11-21 2019-05-31 Bristol-Myers Squibb Company Composes heteroaryle a substitution sulfone pyridine d'alkyle amide
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
CN111936486B (zh) * 2018-03-22 2023-09-22 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物
RS66416B1 (sr) 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene
US20230049130A1 (en) * 2020-01-19 2023-02-16 Crystal Pharmaceutical (Suzhou) Co., Ltd. Deucravacitinib crystal form, preparation method therefor and use thereof
CN114981262A (zh) 2020-12-22 2022-08-30 益方生物科技(上海)股份有限公司 杂芳基化合物及其制备方法和用途
US20240246944A1 (en) 2021-03-16 2024-07-25 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
CN115724830A (zh) * 2021-08-31 2023-03-03 浙江文达医药科技有限公司 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法
CA3236262A1 (fr) 2021-10-25 2023-05-04 Isaac Marx Agents de degradation de tyk2 et leurs utilisations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270730A1 (en) 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
MX2010012703A (es) * 2008-05-21 2010-12-21 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2013091011A1 (fr) * 2011-12-21 2013-06-27 Biota Europe Ltd Composés hétérocycliques d'urée
AU2013204563B2 (en) * 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
EP2922846B1 (fr) 2012-11-08 2018-10-03 Bristol-Myers Squibb Company Composés hétérocycliques substitués par amide, utiles comme modulateurs d'il-12, il-23 et/ou de ifn-alpha
WO2014074660A1 (fr) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Composés pyridyle substitués par alkyl-amide, utiles comme modulateurs d'il-12, il-23 et/ou de réponses à l'ifnα
WO2014181287A1 (fr) * 2013-05-09 2014-11-13 Piramal Enterprises Limited Composés hétérocyclyliques et leurs utilisations
TWI582077B (zh) * 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物
EP2947460A1 (fr) 2014-05-22 2015-11-25 Medizinische Universität Wien Thérapie personnalisée de cancer associé à une inflammation à l'aide de procédés d'évaluation de la susceptibilité d'un sujet pour le traitement avec des antagonistes/inhibiteurs EGFR

Also Published As

Publication number Publication date
CN110267964B (zh) 2022-05-03
KR102602558B1 (ko) 2023-11-14
JP2020502268A (ja) 2020-01-23
JP7046092B2 (ja) 2022-04-01
TW201827423A (zh) 2018-08-01
US10294256B2 (en) 2019-05-21
ES2907008T3 (es) 2022-04-21
KR20190091536A (ko) 2019-08-06
AR110351A1 (es) 2019-03-20
WO2018111787A1 (fr) 2018-06-21
US20180162889A1 (en) 2018-06-14
EP3555111B1 (fr) 2022-01-26
EP3555111A1 (fr) 2019-10-23
CN110267964A (zh) 2019-09-20

Similar Documents

Publication Publication Date Title
MA48602A (fr) Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
MA46453A (fr) Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha
FR25C1021I2 (fr) Composés et compositions destinés à moduler les activités kinase de l'egfr mutant
MA46620A (fr) Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
IL256614A (en) Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated diseases
EP3524603A4 (fr) Inhibiteur de fgfr4, son procédé de préparation et son utilisation pharmaceutique
BR112018007395A2 (pt) 2,4-di-hidróxi-nicotinamidas como agonistas de apj
EP3700536A4 (fr) Compositions et procédés de modulation de la réponse immunitaire par activation de la protéine kinase alpha 1
EP3352795A4 (fr) Compositions et méthodes de modification d'acides nucléiques cibles
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
EP3488361A4 (fr) Système d'enregistrements de correspondance
BR112018011709A2 (pt) inibidores bicíclicos de pad4
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
MX2017003359A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
EP3452407A4 (fr) Méthodes et utilisations aux fins de mesures d'activité protéasique déclenchées à distance
IL261856B (en) Use of masitinib to treat a subpopulation of amyotrophic lateral sclerosis patients
EP3602528A4 (fr) Dispositif d'apprentissage de simulation de piston de seringue pré-rempli
EP3790461C0 (fr) Systèmes de canule de détection
BR112016016274A2 (pt) Ponte da barreira hematoencefálica
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
EP3528813A4 (fr) Composés p2x3 et/ou p2x2/3 et méthodes associées
CL2016001763A1 (es) Antagonistas selectivos de nr2b
EP3551612A4 (fr) Procédé de préparation de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophényl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate et ses polymorphes